Martin-McGill Kirsty J, Marson Anthony G, Tudur Smith Catrin, Jenkinson Michael D
a Institute of Translational Medicine, University of Liverpool and The Walton Centre NHS Foundation Trust , Liverpool , UK.
b Department of Biostatistics , University of Liverpool, Brownlow Hill , Liverpool , UK.
Nutr Cancer. 2018 May-Jun;70(4):643-649. doi: 10.1080/01635581.2018.1460677. Epub 2018 Apr 18.
There is an increasing interest in the use of the ketogenic diet (KD) as an adjuvant therapy for glioma patients. We assessed the tolerability and feasibility of a modified ketogenic diet (MKD) in patients with glioma, along with willingness of patients to participate in future randomized controlled trials. The study was undertaken in two parts; a patient questionnaire and evaluation of the diet. One hundred and seventy-two questionnaires were completed; 69% (n = 119) of the population reported MKD should be offered to patients with glioma and 73% (n = 125) would be willing to try MKD for 3 months. Six male patients with high grade gliomas tried the diet; 4 completed the 3-month feasibility period. Ketosis was achieved in all patients. The only gastrointestinal side effect was constipation (n = 2). Minimal changes were observed in weight, body mass index, fat mass and cholesterol profiles. MKD was well tolerated, with few side effects and is deliverable within a financially viable, NHS service. There is a high level of interest in the diet within the glioma patient community to ensure adequate recruitment for a clinical trial. Further studies are required to demonstrate efficacy and patient benefit before implementing a service.
将生酮饮食（KD）用作胶质瘤患者的辅助治疗方法正受到越来越多的关注。我们评估了改良生酮饮食（MKD）在胶质瘤患者中的耐受性和可行性，以及患者参与未来随机对照试验的意愿。该研究分两部分进行；一部分是患者问卷调查，另一部分是饮食评估。共完成了172份问卷；69%（n = 119）的受访者表示应向胶质瘤患者提供MKD，73%（n = 125）的受访者愿意尝试MKD三个月。六名高级别胶质瘤男性患者尝试了这种饮食；4名患者完成了为期3个月的可行性阶段。所有患者均实现了酮症。唯一的胃肠道副作用是便秘（n = 2）。体重、体重指数、脂肪量和胆固醇水平仅有微小变化。MKD耐受性良好，副作用少，且在国民保健服务体系（NHS）的经济可行范围内即可实施。胶质瘤患者群体对这种饮食有很高的兴趣，以确保为临床试验招募到足够的患者。在实施相关服务之前，还需要进一步研究来证明其疗效和对患者的益处。
